停牌18个月，“癌症早筛第一股”面临强制退市，投资者损失惨重！此前被指财务造假，创始人等多名高管已辞职

Core Viewpoint - Nohui Health, once hailed as the "first stock in cancer early screening," has been suspended from trading on the Hong Kong Stock Exchange for 18 months, potentially facing mandatory delisting due to regulatory rules [1] Group 1: Company Background - Nohui Health was established in 2015 in Hangzhou, Zhejiang, and became the first company in China focused on home early screening for high-incidence cancers, successfully listing on the Hong Kong Stock Exchange in 2021 [3] - The company has commercialized three main products targeting the top three high-incidence cancers in China: Changweiqing®, Pupu Tube®, and Youyou Tube® [3] - Changweiqing® is the only colorectal cancer screening product approved by the National Medical Products Administration in China, suitable for high-risk individuals aged 40-74 [3] Group 2: Financial Issues and Allegations - In August 2023, a short-selling firm, CapitalWatch, released a report alleging financial fraud, claiming that Nohui Health inflated its sales revenue through inventory manipulation, with actual sales for 2022 estimated at 76.95 million, significantly lower than the reported 765 million [4] - Despite management's strong denial and claims of third-party audits, Deloitte refused to endorse the company's financial statements in March 2024, raising concerns about the authenticity of sales data [4] Group 3: Stock Performance and Management Changes - Following the suspension on March 28, 2024, Nohui Health's stock price fell from an initial listing price of 26.66 HKD to 14.14 HKD, nearly halving in value [5] - The company has seen a series of executive departures, including the resignation of the founder and CEO, Zhu Yeqing, in 2025, and the appointment of joint provisional liquidators by the Cayman Islands court [5] - Investors have suffered significant losses, with the valuation of Nohui Health dropping from 14.14 HKD at suspension to nearly zero, with the latest valuation at 0.01 HKD [5] Group 4: Regulatory and Product Concerns - Nohui Health's core product, Changweiqing®, has a registration certificate expiring in November 2025, raising concerns about its future sales and regulatory compliance [5]